Authors
- . Bahareh Valadkhani 1
- . Mona Kargar 2
- . Asieh Ashouri 3
- . Molouk Hadjibabaie 2
- . Kheirollah Gholami 2
- . Ardeshir Ghavamzadeh 4
1 Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2 Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran
3 School of Health, Guilan University of Medical Sciences, Rasht, Iran
4 Department of Hematology‑Oncology, Hematology‑Oncology and SCT Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Objective: Opportunistic infections like cytomegalovirus (CMV) are among the
primary causes of morbidity and mortality in patients undergoing hematipoetic stem
cell transplantation (HSCT). This infection is frequently seen in early postengraftment
period. So we determined to find the risk factors associated with CMV reactivation.
Methods: We retrospectively evaluated the medical records of 126 consecutive patients
who underwent allogenic‑HSCT from peripheral blood stem cells from August 2011 to
February 2013 in Shariati Hospital. We included HSCT patients with 15 years of age
or older, who survived at least 100 days after transplantation. CMV reactivation was
detected based on the weekly PP65 assessment. Patients with 10 or more positive cells
per 50,000 cells were defined as having high‑level antigenemia.
Findings: From 126 patients which included in this study, 76 were male (60%). CMV
antigenemia was documented in 43 patients (34%). The median time to CMV infection
was 40 days (range: 3–77) after transplantation. The incidence of high‑level antigenemia
during the first 100 days following HSCT was 11%.
Conclusion: We found that the significant risk factor for CMV antigenemia in multivariate
analysis was prior graft‑versus‑host disease (GVHD) experience and higher donor age. For
high‑level antigenemia, GVHD or duration of its treatment was significant determinant.
Keywords
recovery following hematopoietic stem cell transplantation.
Brain Behav Immun 2013;30 Suppl: S68‑74.
2. Wingard JR. Opportunistic infections after blood and marrow
transplantation. Transpl Infect Dis 1999;1:3‑20.
3. Watcharananan SP, Kiertiburanakul S, Piyatuctsanawong W,
Anurathapan U, Sungkanuparph S, Pakakasama S,
et al. Cytomegalovirus, adenovirus, and polyomavirus
co‑infection among pediatric recipients of allogeneic stem
cell transplantation: Characteristics and outcome. Pediatr
Transplant 2010;14:675‑81.
4. Reinke P, Prösch S, Kern F, Volk HD. Mechanisms of human
cytomegalovirus (HCMV) (re) activation and its impact on
organ transplant patients. Transpl Infect Dis 1999;1:157‑64.
5. PeresRM, CostaCR, AndradePD, BononSH, AlbuquerqueDM,
de OliveiraC, etal. Surveillance of active human cytomegalovirus
infection in hematopoietic stem cell transplantation (HLA
sibling identical donor): Search for optimal cutoff value by
real‑time PCR. BMC Infect Dis 2010;10:147.
6. Ksouri H, Eljed H, GrecoA, LakhalA, Torjman L, AbdelkefiA, et al. Analysis of cytomegalovirus (CMV) viremia using
the pp65 antigenemia assay, the amplicor CMV test, and
a semi‑quantitative polymerase chain reaction test after
allogeneic marrow transplantation. Transpl Infect Dis
2007;9:16‑21.
7. Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J,
Stadler M, et al. Tetramer monitoring to assess risk factors for
recurrent cytomegalovirus reactivation and reconstitution of
antiviral immunity post allogeneic hematopoietic stem cell
transplantation. Transpl Infect Dis 2011;13:222‑36.
8. Kim DH, Kim JG, Lee NY, Sung WJ, Sohn SK, Suh JS, et al.
Risk factors for late cytomegalovirus infection after allogeneic
stem cell transplantation using HLA‑matched sibling donor:
Donor lymphocyte infusion and previous history of early
CMV infection. Bone Marrow Transplant 2004;34:21‑7.
9. Barkholt L, Lewensohn‑Fuchs I, Ericzon BG, Tydén G,
Andersson J. High‑dose acyclovir prophylaxis reduces
cytomegalovirus disease in liver transplant patients. Transpl
Infect Dis 1999;1:89‑97.
10. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in
hematopoietic stem cell transplant recipients. Infect Dis Clin
North Am 2010;24:319‑37.
11. Cho BS, Yahng SA, Kim JH, Yoon JH, Shin SH, Lee SE,
et al. Impact of cytomegalovirus gastrointestinal disease
on the clinical outcomes in patients with gastrointestinal
graft‑versus‑host disease in the era of preemptive therapy.
Ann Hematol 2013;92:497‑504.
12. El‑Cheikh J, Devillier R, Crocchiolo R, Fürst S, Calmels B,
Faucher C, et al. Impact of pretransplant donor and recipient
cytomegalovirus serostatus on outcome for multiple myeloma
patients undergoing reduced intensity conditioning allogeneic
stem cell transplantation. Mediterr J Hematol Infect Dis
2013;5:e2013026.
13. George B, Pati N, Gilroy N, Ratnamohan M, Huang G,
Kerridge I, et al. Pre‑transplant cytomegalovirus (CMV)
serostatus remains the most important determinant of
CMV reactivation after allogeneic hematopoietic stem cell
transplantation in the era of surveillance and preemptive
therapy. Transpl Infect Dis 2010;12:322‑9.
14. George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS,
Bradstock KF, et al. A risk score for early cytomegalovirus
reactivation after allogeneic stem cell transplantation identifies
low‑, intermediate‑, and high‑risk groups: Reactivation
risk is increased by graft‑versus‑host disease only in the
intermediate‑risk group. Transpl Infect Dis 2012;14:141‑8.
15. Miller W, Flynn P, McCullough J, Balfour HH Jr, Goldman A,
Haake R, et al. Cytomegalovirus infection after bone marrow
transplantation: An association with acute graft‑v‑host disease.
Blood 1986;67:1162‑7.
16. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H,
et al. Cytomegalovirus antigenemia and outcome of
patients treated with pre‑emptive ganciclovir: Retrospective
analysis of 241 consecutive patients undergoing allogeneic
hematopoietic stem cell transplantation. Bone Marrow
Transplant 2003;32:801‑7.
17. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE,
Clift RA, et al. Clinical manifestations of graft‑versus‑host
disease in human recipients of marrow from HL‑A‑matched
sibling donors. Transplantation 1974;18:295‑304.
18. Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K,
et al. Pre‑emptive therapy against cytomegalovirus (CMV)
disease guided by CMV antigenemia assay after allogeneic
hematopoietic stem cell transplantation: A single‑center
experience in Japan. Bone Marrow Transplant 2001;27:437‑44.
19. Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S,
et al. Low‑dose valgancyclovir as cytomegalovirus
reactivation prophylaxis in allogeneic haematopoietic stem
cell transplantation. Infez Med 2012;20 Suppl 2:26‑34.
20. Cantoni N, Hirsch HH, Khanna N, Gerull S, BuserA, Bucher C,
et al. Evidence for a bidirectional relationship between
cytomegalovirus replication and acute graft‑versus‑host
disease. Biol Blood Marrow Transplant 2010;16:1309‑14.
21. Schetelig J, Oswald O, Steuer N, RadonicA, Thulke S, Held TK,
et al. Cytomegalovirus infections in allogeneic stem cell
recipients after reduced‑intensity or myeloablative conditioning
assessed by quantitative PCR and pp65‑antigenemia. Bone
Marrow Transplant 2003;32:695‑701.
22. Ljungman P, Perez‑Bercoff L, Jonsson J, Avetisyan G,
Sparrelid E, Aschan J, et al. Risk factors for the development
of cytomegalovirus disease after allogeneic stem cell
transplantation. Haematologica 2006;91:78‑83.
23. Ross SA, Novak Z, Pati S, Boppana SB. Overview of the
diagnosis of cytomegalovirus infection. Infect Disord Drug
Targets 2011;11:466‑74.
)